CTOs on the Move

EMD Millipore

www.emdmillipore.com

 
"At EMD Millipore, one of the top three investors in R&D in the Life Science Tools industry, we develop cutting-edge technologies and services for bioscience research and biopharmaceutical manufacturing. Innovation drives everything we do. And it’s reinforced by our collaborative culture, pioneering spirit and unwavering focus on the world’s most challenging human health issues. EMD Millipore, known outside North America as Merck Millipore, is part of the Merck Group, a global company with 40,000 employees in more than 60 countries. EMD Millipore is a division of Merck KGaA, Darmstadt, Germany."
  • Number of Employees: 1K-5K
  • Annual Revenue: $500M-1 Billion

Executives

Name Title Contact Details
Kerry Roche Lentine
Director - Technology Management Profile

Similar Companies

Hopedale Medical Complex

Hopedale Medical Complex is a Hopedale, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aldie Foundation Inc

Aldie Foundation Inc is a Doylestown, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Saint Luke's Health System

Saint Lukes Health System is a non-profit hospital network in the bi-state Kansas City metro area, located in northeast Kansas and northwest Missouri.

Advanced Health Education Center

Advanced Health Education Center is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

StemCells

StemCells, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery primarily in the United States. Its lead therapeutic product candidate, HuCNS-SC cells (purified human neural stem cells), is in development as a potential treatment for a range of central nervous system disorders. The company has conducted a Phase I clinical trial in Pelizaeus-Merzbacher disease, a fatal myelination disorder in children. It is also conducting a Phase I/II clinical trial in chronic spinal cord injury; and has initiated a Phase I/II clinical trial in dry age-related macular degeneration, as well as is pursuing preclinical studies in Alzheimer’s disease. In addition, the company markets a rage of proprietary cell culture products, research grade human cells, and antibody reagents under the SC Proven brand. The proprietary cell culture products include iSTEM, GS1-R, GS2-M, RHB-A, RHB-Basal, NDiff227, NDiff N2, and NDiff N27 supplements, as well as HEScGRO and ESGRO Complete; and antibody reagents comprise STEM24, STEM101, STEM121, and STEM123, which can be used for cell detection, isolation, and characterization. Further, StemCells is involved in developing and commercializing applications of its technologies to enable stem cell-based research. The company sells its tools and technologies products to researchers at academic institutions, pharmaceutical and biotechnology companies, and government laboratories. StemCells, Inc. was founded in 1988 and is headquartered in Newark, California.